Literature DB >> 16458775

Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve?

Mira Keyes1, Devin Schellenberg, Veronika Moravan, Michael McKenzie, Alexander Agranovich, Tom Pickles, Jonn Wu, Mitchell Liu, Joseph Bucci, W James Morris.   

Abstract

PURPOSE: To evaluate the incidence and factors predictive of acute urinary retention (AUR) in 805 consecutive patients treated with prostate brachytherapy monotherapy and to examine the possible effect of a learning curve. METHODS AND MATERIALS: Between July 1998 and November 2002, 805 patients were treated with prostate brachytherapy. Low-risk patients (Gleason Score (GS) < or = 6; prostate specific antigen (PSA) < or = 10, and < or = T2b [UICC 1997]) received implant alone. Patients with prostate volume of 50 cc or more, GS = 7, or PSA = 10 to 15 received 6 months of androgen suppression (AS) with brachytherapy. Patient, treatment, and dosimetric factors examined include baseline prostate symptom score (IPSS), diabetes, vascular disease, PSA, Gleason score, clinical stage, AS, ultrasound planning target volume (PUTV), postimplant prostate volume (obtained with "Day 30" postimplant CT), CT:PUTV ratio (surrogate for postimplant edema), number of seeds, number of needles, number of seeds per needle, dosimetric parameters (V100, V150, and D90), date of implant (learning curve), and implanting oncologists. Univariate and multivariate analyses were carried out.
RESULTS: Acute urinary retention in the first 200 patients was 17% vs. 6.3% in the most recently treated 200 patients (p = 0.002). Overall AUR was 12.7%, and prolonged urinary obstruction incidence (> 20 days) was 5%. On multivariate analysis, factors predictive of any AUR include baseline IPSS (p = < 0.004), CT:PUTV ratio (p = < 0.001), PUTV (p = < 0.001), and implant order (learning curve) (p = 0.001). Factors predictive for "prolonged" catheterization (> 20 days) on multivariate analysis include IPSS (p < 0.01), number of needles (p < 0.001), diabetes mellitus (p = 0.048), and CT:PUTV ratio (p < 0.001)
CONCLUSION: Over the years, our AUR rate has fallen significantly (from 17% to 6.3%). On multivariate analysis, highly significant factors include IPSS, PUTV, CT:PUTV ratio (i.e., degree of prostate edema), and order of implant (learning curve). Over the course of the program, we have deliberately reduced the number of needles and OR time per patient, which have potentially minimized intraoperative trauma and may have contributed to less toxicity. A learning curve in prostate brachytherapy programs affect not only the outcome but also the toxicity from the treatment.

Entities:  

Mesh:

Year:  2006        PMID: 16458775     DOI: 10.1016/j.ijrobp.2005.04.056

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  Secondary effects and biochemical control in patients with early prostate cancer treated with (125)-I seeds.

Authors:  V Morillo; J L Guinot; I Tortajada; J V Ricós; L Arribas; M Maroñas; M Estornell; J Casanova
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

2.  Canadian prostate brachytherapy in 2012.

Authors:  Mira Keyes; Juanita Crook; W James Morris; Gerard Morton; Tom Pickles; Nawaid Usmani; Eric Vigneault
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

3.  Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer.

Authors:  E Le Fur; J P Malhaire; D Baverez; F Delage; M A Perrouin-Verbe; F Schlurmann; S Guerif; G Fournier; O Pradier; A Valeri
Journal:  Strahlenther Onkol       Date:  2012-11-11       Impact factor: 3.621

4.  The use of a memokath prostatic stent for obstructive voiding symptoms after brachytherapy.

Authors:  G W de Graaf; P E F Stijns; W A Scheepens; R J A van Moorselaar; A J M Hendrikx
Journal:  Curr Urol       Date:  2013-07-28

5.  The impact of trainee involvement on outcomes in low-dose-rate brachytherapy for prostate cancer.

Authors:  Talha Shaikh; Lora Wang; Karen Ruth; Mark Hallman; David Y Chen; Richard E Greenberg; Jinsheng Li; Kevin Crawford; Eric M Horwitz
Journal:  Brachytherapy       Date:  2016-01-29       Impact factor: 2.362

6.  A Population-based Statistical Model for Investigating Heterogeneous Intraprostatic Sensitivity to Radiation Toxicity After 125I Seed Implantation.

Authors:  Kazuma Kobayashi; Naoya Murakami; Kana Takahashi; Koji Inaba; Hiroshi Igaki; Ryuji Hamamoto; Jun Itami
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

7.  Prostate brachytherapy in New South Wales: patterns of care study and impact of caseload on treatment quality.

Authors:  Stephen R Thompson; Geoff P Delaney; Gabriel S Gabriel; Michael A Izard; George Hruby; Raj Jagavkar; Joseph Bucci; Michael B Barton
Journal:  J Contemp Brachytherapy       Date:  2014-11-12

8.  Acute urinary morbidity after a permanent 125I implantation for localized prostate cancer.

Authors:  Saiji Ohga; Katsumasa Nakamura; Yoshiyuki Shioyama; Katsunori Tatsugami; Tomonari Sasaki; Takeshi Nonoshita; Tadamasa Yoshitake; Kaori Asai; Hideki Hirata; Seiji Naito; Hiroshi Honda
Journal:  J Radiat Res       Date:  2014-07-25       Impact factor: 2.724

9.  Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review.

Authors:  Simon Zuber; Susan Weiß; Dieter Baaske; Michael Schöpe; Simon Stevens; Stephan Bodis; Daniel R Zwahlen
Journal:  Radiat Oncol       Date:  2015-02-22       Impact factor: 3.481

10.  Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer.

Authors:  W Tristram Arscott; Leonard N Chen; Nathan Wilson; Aditi Bhagat; Joy S Kim; Rudy A Moures; Thomas M Yung; Siyuan Lei; Brian T Collins; Keith Kowalczyk; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  Radiat Oncol       Date:  2014-07-24       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.